newsfilter
← Latest News
GlobeNewswire·

CytomX Therapeutics Announces Business Update and Company Milestones for 2026

  • CytomX Therapeutics expects Phase 1 colorectal cancer expansion data for varsetatug masetecan (CX-2051) in Q1 2026.
  • A Phase 1 combination study of varsetatug masetecan with bevacizumab in colorectal cancer is scheduled to begin in Q1 2026, with initial data expected in the first half of 2027.
  • Initial Phase 1 combination data for CX-801 (masked interferon-alpha-2b) with KEYTRUDA in advanced melanoma is anticipated by the end of 2026.
  • CEO Sean McCarthy will present at the 44th Annual JP Morgan Healthcare Conference on January 14, 2026.
  • Varseta-M Phase 1 dose expansions are ongoing across 7.2 mg/kg, 8.6 mg/kg, 10 mg/kg doses administered every three weeks to select doses for a potential registrational study.
  • Total Phase 1 enrollment for varsetatug masetecan is projected to reach approximately 100 patients by the Q1 2026 update.
  • The company aims to align with the FDA in 2026 regarding a potential registrational study design for varsetatug masetecan monotherapy in advanced colorectal cancer.
  • Initiation of Phase 1 expansion cohorts for varsetatug masetecan in additional indications is planned for the second half of 2026.
  • CX-801 monotherapy dose escalation has reached its fourth dose level 2026 with well-tolerated results at doses exceeding the approved unmasked IFNα2b dose.
  • CX-801 combination dose escalation with KEYTRUDA is currently enrolling the second dose level following initiation in May 2025.
  • CytomX plans to advance varsetatug masetecan into earlier lines of colorectal cancer treatment to address high unmet medical need.